MD Anderson Researchers To Assess VolitionRx’s NuQ® Assay In Anaplastic Prostate Cancer Diagnosis

MD Anderson Researchers To Assess VolitionRx’s NuQ® Assay In Anaplastic Prostate Cancer Diagnosis
VolitionRx Limited, a life sciences company developing blood-based diagnostic tests for different types of cancer, has announced a collaboration study with the University of Texas MD Anderson Cancer Center’s Department of Genitourinary Medical Oncology. MD Anderson researchers will use VolitionRx’s NuQ® assay to distinguish anaplastic prostate cancer, an aggressive form of prostate cancer, from castration-resistant prostate

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *